Followers | 67 |
Posts | 3747 |
Boards Moderated | 0 |
Alias Born | 08/30/2009 |
Tuesday, April 13, 2021 10:18:07 PM
All of these countries look to the FDA for guidance for therapeutics. Our FDA has let them down.
I’ll say it again....the FDA’s cozy relationship with Big Pharma, whose drugs have all been failures in really sick COVID patients (sans Roche’s tocilizumab), has cost millions of lives worldwide.
Because all the Big Pharma companies failed, the FDA basically did nothing. Dr. Woodcock herself admitted all of the trials on actually sick patients were underpowered (the FDA signs off on trial design) when she participated in a forum with AMA President, Susan Bailey. As such, none of them were powered to hit a primary endpoint. So, basically, the therapeutic trials were a waste - UNLESS the FDA actually starts following the “safe and may be effective” criteria for an EUA. Then, other countries, who are struggling BADLY right now, can get medications like leronlimab, aviptadil, abs tocilizumab (although they have manufacturing shortfall). The FDA could also do an Operation Warp Speed for therapeutics as well!
How many people have to die for a p-value, Dr. Woodock?
So, let’s analyze the FDA’s record on COVID:
HCQ - failed EUA that was granted despite the data suggesting its failure
Plasma - failed EUA granted without any significant study showing benefit; only that if plasma is given sooner it any be more beneficial. But, at no time was a placebo-controlled trial done for its EUA. Those trials failed.
Remdesivir - failed EUA despite studies in China showing no benefit. Association with NIAID and Gilead got the goal posts moved on its study. It showed no benefit in severely ill patients and its 4 day reduction in hospitalization length didn’t hold up in larger trials.
Regeneron/Lily MABs - I told this page’s followers back in November these drugs would fail due to mutations in my talk about why leronlimab was better than bamlanivimab. And, guess what? States are now not using those drugs because the mutations rendered them useless. This will be another pretty much failed EUA. While these drugs had initial promise, much like with the vaccines, EUA without logistics made them hard to obtain. This would compounded by the need for an infusion in an overwhelmed healthcare system (which was another colossal US healthcare failure).
Baricitinib? (laughing emoji here)
As a physician, and as a human who has had a friend to die and a close friend lose his dad, what the FDA has done is indefensible, unethical, and a violation of the Hipppcratic Oath. When promising drugs have shown they’re safe, not allowing them to be used by the FDA is a violation of “first do no harm.”
It’s past time we demand better from our government. We have let the world down!
USFDA
Recent CYDY News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:01:55 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM
Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • INTV • May 15, 2024 10:30 AM